Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;36(2):205-206.
doi: 10.1007/s40263-021-00892-z. Epub 2022 Jan 11.

Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status"

Ioline D Henter  1 , Lawrence T Park  1 , Carlos A Zarate Jr  2
Affiliations
Comment

Authors' Reply to Pappagallo et al.: Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status"

Ioline D Henter et al. CNS Drugs. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.

Comment on

References

    1. Pappagallo M, Inturrisi C, Manfredi P. Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.” CNS Drugs. 2021. 10.1007/s40263-021-00891-0. - DOI - PMC - PubMed
    1. Henter ID, Park LT, Zarate CAJ. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35:527–43. 10.1007/s40263-021-00816-x. - DOI - PMC - PubMed
    1. US Drug Enforcement Administration. Drug and Chemical Information Section: Methadone. Springfield, VA, US Drug Enforcement Administration, Diversion, Control Division. 2019. https://www.deadiversion.usdoj.gov/drug_chem_info/methadone/methadone.pdf.
    1. Moryl N, Tamasdan C, Tarcatu D, Thaler HT, Correa D, Steingart R, et al. A phase I study of D-methadone in patients with chronic pain. J Opioid Manag. 2016;12:47–55. - PubMed
    1. Hagler G. BioSpace: Relmada Therapeutics developing REL-1017 to treat major depression. April 21, 2020. 2020 [cited 2020. https://www.biospace.com/article/relmada-developing-rel-1017-to-treat-ma.... Accessed 21 Sept 2020.